← Patent-cliff monitor small molecule POMALYST POMALIDOMIDE
Loss of exclusivity December 2031 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name POMALYST Active ingredient POMALIDOMIDE Strength 4MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval February 2013 Marketing status RX
Listed patents Patent Expires Type 8828427*PED December 2031 — 8828427 June 2031 substance, product 9993467*PED November 2030 — 10555939*PED November 2030 — 10555939 May 2030 product 9993467 May 2030 product
Regulatory exclusivity Code Expires PED November 2027 ODE-296 May 2027 ODE-297 May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.